Elizabeth Forsythe
Family · Oklahoma City, OKNPI 1538662267
Payments from drug & device makers
Across 234 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Mayne Pharma Commercial LLC$583
- Astellas Pharma US Inc$431
- Bayer$261
- Agile Therapeutics, Inc.$258
- Millicent US Inc$234
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,48098%
- Education$862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 59 | $1,121 |
| Mayne Pharma Commercial LLC | 24 | $583 |
| Astellas Pharma US Inc | 19 | $431 |
| Bayer | 12 | $261 |
| Agile Therapeutics, Inc. | 14 | $258 |
| Millicent US Inc | 14 | $234 |
| Exeltis, USA Inc. | 11 | $213 |
| Sage Therapeutics, LLC | 12 | $209 |
| Organon | 10 | $173 |
| Sumitomo Pharma America, Inc. | 6 | $129 |
| Lilly USA, LLC | 7 | $117 |
| Arcutis Biotherapeutics, Inc. | 1 | $91 |
| Merck | 5 | $90 |
| Exact Sciences | 6 | $89 |
| Hologic Sales And Service, LLC | 5 | $87 |
| Novo Nordisk | 5 | $80 |
| Avion Pharmaceuticals | 4 | $74 |
| Myovant Sciences Inc. | 4 | $72 |
| Therapeuticsmd, Inc. | 4 | $64 |
| Scynexis, Inc. | 4 | $56 |
| Evofem Biosciences, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Pfizer | 1 | $19 |
| Roche Diagnostics Corporation | 1 | $17 |
| Davol Inc. | 1 | $16 |
| Mylan Pharmaceuticals Inc. | 1 | $16 |
| Mission Pharmacal Company | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orilissa$112
How this compares
$4,566 in reported general payments places this provider in the 90th percentile of 2,026 family providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 18 | $19,598 |
| Estradiol | 16 | $340 |
| Fluconazole | 11 | $81 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $117 | $19,59818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,026 family providers in Oklahoma.
Other family in Oklahoma City
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Lacey HillOklahoma City$20K
- Julia John SamuelOklahoma City$17K
- Kristina SnyderOklahoma City$15K
- Lindi CiglarOklahoma City$15K
- Shymol JohnOklahoma City$14K
- Xiomara PorrasOklahoma City$12K
- Anne DudeOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.